Marizyme_logo - Full Size Original-2456x552.png
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
April 16, 2024 07:00 ET | Marizyme Inc.
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics,...
Marizyme_logo - Full Size Original-2456x552.png
Marizyme CEO Delivers Business Update
October 23, 2023 09:00 ET | Marizyme Inc.
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the...
Marizyme_logo - Full Size Original-2456x552.png
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
October 06, 2023 09:00 ET | Marizyme Inc.
DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL, Oct. 06, 2023 (GLOBE...
Marizyme_logo - Full Size Original-2456x552.png
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
May 10, 2023 08:00 ET | Marizyme Inc.
JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated...
Marizyme_logo - Full Size Original-2456x552.png
Marizyme CEO Delivers Business Update
May 03, 2023 08:00 ET | Marizyme Inc.
JUPITER, FL, May 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the...
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
January 05, 2022 08:30 ET | Marizyme Inc.
Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark...
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
December 23, 2021 15:24 ET | Marizyme Inc.
JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health...
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
December 03, 2021 16:30 ET | Marizyme Inc.
JUPITER, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and...
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
December 03, 2021 10:37 ET | Marizyme Inc.
Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to...
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
November 16, 2021 14:55 ET | Marizyme Inc.
JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief...